We observed that palbociclib paradoxically stabilizes p21/p27‐free cyclin D‐CDK4/6 complexes that become hyperactive upon palbociclib withdrawal, potentially inducing a burst of tumour cell cycle progression that might open a window of increased responsiveness to genotoxic therapies [64]. Here, CDK4 is linked to neoplasm.